Related Experiment Video
Updated: Aug 30, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
[GPIIB/IIIA blockade after high-risk angioplasty: new perspectives]
Zahreddine Smiri1, Dhaker Lahidheb, Néjib Hajlaoui
1Service de Cardiologie, Hôpital Militaire Principal d'Instruction de Tunis.
Abstract:
The treatment of acute coronary syndromes knows today revolution, with the clinical use of platelet glycoprotein IIb/IIIa inhibitors. The benefit of these agents as adjunctive treatment for percutaneous coronary intervention has been substantial and consistently proved among trials; however patients undergoing revascularization after drug discontinuation demonstrated a moderate event reduction. In this analysis, including the entire large-scale trial experience of intravenous glycoprotein IIb/IIIa inhibitors, we try to evaluate this therapeutic class in the high risk coronary intervention, in patients with acute coronary syndromes primarily medically managed, and in combination therapy with thrombolytics in the acute myocardial infarction. The purpose was to demonstrate the reduction of cardiac events after administration of this drug in the different indications and to precise their different adverse effects.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Angina IV: Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease V: Interprofessional Care